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1200ince their introduction, questions have been raised regarding
he relative clinical and economic attractiveness of drug-eluting
tents (DES) versus other treatment strategies (1). Economic
nalyses were conducted for each of the major DES (Cypher
Cordis Corporation, Bridgewater, New Jersey], Taxus [Bos-
on Scientific, Natick, Massachusetts], and Endeavor
Medtronic, Minneapolis, Minnesota]) in their primary DES
See page 1236
ersus bare-metal stent (BMS) clinical trials, and each of these
nalyses demonstrated that DES are able to recoup most of
heir higher initial costs through reductions in repeat target
vessel revascularization (TVR)
procedures during the first
follow-up year (2–4). Although a
number of studies have compared
DES versus DES clinical out-
comes, none have evaluated both
long-term clinical and economic
outcomes (5–8).
The ENDEAVOR III (Ran-
domized Controlled Trial of the
Medtronic Endeavor Drug [ABT-
578] Eluting Coronary Stent Sys-
tem Versus the Cypher Sirolimus-
Eluting Coronary Stent System in
De Novo Native Coronary Artery
Lesions) clinical trial compared
the Endeavor zotarolimus-eluting
stent (ZES) with the Cypher
sirolimus-eluting stent (SES) (9).
Because the ENDEAVOR II
(Randomized Controlled Trial to
Evaluate the Safety and Efficacy of
the Medtronic AVE ABT-578
Eluting Driver Coronary Stent in
De Novo Native Coronary Artery
Lesions) economic analysis demon-
strated that the benefits of ZES
versus BMS in reducing repeat
VR procedures might continue well beyond the first follow-up
ear, we decided to evaluate the clinical and economic attractive-
ess of ZES versus SES with 3-year follow-up information from
he ENDEAVOR III clinical trial. Our objectives were to
ompare treatment-related differences for subjects receiving ZES
ersus SES with regard to clinical outcomes, economic outcomes,
nd comprehensive cost-effectiveness (incremental medical costs/
uality-adjusted life year [QALY] saved).
ethods
atient population and treatment protocol. The EN-
bbreviations and
cronyms
MS  bare-metal stent(s)
ABG  coronary artery
ypass graft
K-MB  creatine kinase-
yocardial band
ES  drug-eluting stent(s)
RG  diagnosis-related
roup
ACE  major adverse
ardiac events
I  myocardial infarction
CI  percutaneous
oronary intervention
ES  paclitaxel-eluting
tent(s)
ALY  quality-adjusted life
ear
ES  sirolimus-eluting
tent(s)
LR  target lesion
evascularization
VR  target vessel
evascularization
ES  zotarolimus eluting
tent(s)EAVOR III clinical trial randomly assigned 436 subjects Co receive either the ZES (n  323) or the SES (n  113)
9). Subjects undergoing elective percutaneous coronary
ntervention (PCI) were included if their lesion length was
4 to 27 mm, the reference vessel diameter was 2.5 to 3.5
m, and they underwent intracoronary stenting in a single,
ntreated, native coronary artery. The primary study end
oint, as assessed by quantitative coronary angiography, was
n-segment late lumen loss at 8-month follow-up.
Although the ENDEAVOR III clinical trial showed no
ifference in target vessel failure for subjects receiving ZES
ersus SES, it did reveal a difference in nonfatal myocardial
nfarction (MI). Due to the uncertain economic implica-
ions of these results, a plan was submitted to this study’s
ublications committee on March 24, 2008, for the evalu-
tion of clinical and economic outcomes of subjects receiv-
ng ZES versus SES with 3-year follow-up results from the
NDEAVOR III trial. The study protocol for the EN-
EAVOR III trial was approved by the institutional review
oard at each study site and all study subjects consented to
articipate before treatment. The Duke University Medical
enter’s institutional review board approved the long-term
linical and economic analysis protocol.
tudy data identiﬁcation. Clinical events used in the eco-
omic study were identified from ENDEAVOR III case
eport form and major adverse cardiac event (MACE)
nformation. Serious adverse event records were used to
dentify non-MACE hospital stays, and Medical Dictionary
or Regulatory Activities preferred terms from adverse
vents were used to group hospital stays for medical cost
ssignments. All study subjects were assigned an index
rocedure episode of care. Study events were used to define
ollow-up period episodes of care. We defined inpatient
tays by the occurrence of a MACE or serious adverse event
ospital stay. Deaths not associated with a hospital stay
ere the only outpatient episodes.
We used the logic of the Centers for Medicare and
edicaid Services Medicare Severity Diagnosis Related
rouper to assign diagnosis-related groups (DRGs) to
pisodes of care (10). These assignments were then audited
y a trained medical record professional. Medical costs and
engths of stay for cardiovascular episodes of care were
stimated with Medicare’s 2008 national average payment
mounts (calculated with an average hospital Medicare base
ate of $4,893) and arithmetic mean lengths of stay by DRG
11,12). For noncardiovascular episodes, these values were
ssigned with Medicare’s national average relative weight
nd arithmetic mean length of stay. We estimated DRG-
pecific costs for physician services with published sources
nd adjusted them to 2008 values with the consumer price
ndex medical care component (13). Because Medicare’s
ayment amounts for DES DRGs do not include the costs
or specific stent types, we included these by adding the
stimated 2008 unit costs ($2,100) for the Endeavor and
ypher stents to balloon angioplasty procedure reimburse-
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1201ent amounts (data on file, Medtronic Cardiovascular,
anta Rosa, California). The type of repeat PCI procedure
as not identified in the ENDEAVOR III case report
orm, so we used results for repeat PCI procedures at Duke
niversity Medical Center during the ENDEAVOR III
tudy period to define a distribution of 13% balloon angio-
lasty, 19% BMS, and 68% DES (14).
Previously defined methods were used to assign quality-
f-life weights to specific clinical events throughout the
-year study period (15). First, a 0.79 QALY adjustment
epresenting a revascularization procedure was assigned to
ll subjects for their index procedure year. Next, a 0.85
ALY adjustment, representing subjects having coronary
rtery disease, was assigned to all years without a revascu-
arization procedure. During the year that subjects under-
ent repeat revascularization procedures, this QALY esti-
ate was decreased to 0.79. When subjects experienced a
onfatal MI, they received a permanent 0.88 relative utility
eight adjustment. Lastly, a quality-adjusted life day dec-
ement (.0028 QALY) was issued for each day of estimated
ength of stay during a hospital stay (16).
tatistical analyses. STUDY OUTCOMES: CLINICAL OUTCOMES.
ll study outcomes were assessed at 3-year follow-up. The
ndividual study outcomes included death, stroke, nonfatal
I, TVR (PCI, CABG, and total), non-TVR (PCI,
ABG, and total), total revascularizations (PCI, CABG,
nd total), hospital stays (revascularization, other cardiac,
nd noncardiac), survival and quality-adjusted survival (both
ith and without discounting at 3% per annum), and total
ollow-up period length of stay. Composite study outcomes
ncluded death or MI and death or MI or TVR.
TUDY OUTCOMES: MEDICAL COSTS. Medical costs were
eported at annual increments (first year, second year, and
hird year) and cumulatively for the 3-year follow-up period
with and without discounting at 3% per annum).
NTENTION TO TREAT ANALYSES: INDEX PROCEDURE.
aseline clinical characteristics and index procedure re-
ource use information are presented as percentages for
iscrete variables and as medians with interquartile ranges
or continuous variables. The chi-square statistic is used to
ssess differences between dichotomous variables, and the
ruskal-Wallis test is used to assess differences between
ontinuous variables.
NTENTION TO TREAT ANALYSES: FOLLOW-UP PERIOD.
ollow-up period clinical outcomes, number of hospital
tays, survival, quality-adjusted survival, and medical costs
re reported as 3-year cumulative values by treatment (ZES
r SES) with differences, 95% confidence intervals, and p
alues. Additionally, medical costs are presented by annual
ime periods. Analyses of follow-up period results were
erformed on partitioned data with generalized linear mod-
ls with empirical standard errors and an adjustment for
ensoring (17,18). Statistical analyses were performed with
AS software (version 8.2 or higher, SAS Institute, Cary, 3orth Carolina). Figures are used to supplement model
esults by depicting changes in clinical event rates and
edical costs during the follow-up period.
OST-EFFECTIVENESS ANALYSES. We performed a compre-
ensive cost-effectiveness analysis to estimate the incremen-
al total medical costs (Costs)/QALY saved with the use
f ZES versus SES during the 3-year follow-up period:
COSTSZES  COSTSSES QALYZES  QALYSES. This
ost-effectiveness ratio was calculated with estimates of the
uantities shown in the preceding text. The variability of the
ost-effectiveness ratios was assessed with a nonparametric
ootstrap procedure. Results are shown as mean values for
he ratio with the percent of bootstrap samples for which the
ES versus SES treatment strategy cost $50,000/QALY
aved (19,20). We calculated incremental values for total
edical costs, quality-adjusted survival, and the comprehen-
ive cost-effectiveness ratio with a 3% annual discount rate
djustment.
esults
ndex procedure. Subjects receiving ZES versus SES were
ell-matched with regard to age and race; however, more
omen received ZES than received SES (Table 1). Al-
hough subjects receiving either stent type typically had 1 or
ore cardiac risk factors, less than one-third of patients had
ither a history of MI or a prior revascularization procedure.
ost subjects underwent revascularization because of an-
ina or MI, and approximately 40% had multivessel coro-
ary artery disease. During the index DES procedure, most
ubjects received pretreatment with balloon angioplasty, and
6.9% received a single intracoronary stent. There were no
nstances of emergency bypass surgery, and post-procedural
ength of stay was similar in both study arms.
-year outcomes. Over a 3-year follow-up period, the use of
ES versus SES led to a significant reduction in MI and
eath or MI but a higher rate of CABG procedures (target
essel, nontarget vessel, and total) (Table 2, Fig. 1). Of 18
tudy deaths, 8 occurred in SES subjects (2 cardiac and 6
oncardiac), whereas 10 occurred in ZES subjects (1 cardiac
nd 9 noncardiac). The MIs for subjects receiving either
tent type largely were non–Q-wave, and they occurred
rimarily during the index hospital stay. In contrast, a
isproportionate number of TVR procedures occurred at
pproximately the time of protocol-mandated follow-up
ngiography (months 7 to 9). Overall, there were only 5
tent thrombotic events in this study (2 SES and 3 ZES)
hat were associated with 3 deaths, 1 nonfatal MI, and 1
CI TVR procedure. There were no treatment-related
ifferences in the resource use outcomes of hospital stays
nd total length of stay, all at 3-year follow-up (Table 3).
-year quality-adjusted survival and medical costs. At
-year follow-up, subjects receiving ZES versus SES had
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1202imilar survival and quality-adjusted survival (undis-
ounted and discounted) (Table 4, Fig. 2). The use of the
ES versus SES was associated with a nonsignificant
ifference in total medical costs (undiscounted and dis-
ounted) (Table 4, Fig. 3).
ost-effectiveness analyses. In 500 bootstrap samples, the
Table 1. Demographic Data and Patient Characteristics
Characteristic
Age, median (25th, 75th percentile)
Female (%)
Minority race (%)
History of cigarette smoking (%)
Diabetes mellitus (%)
Hyperlipidemia (%)
Hypertension (%)
History of MI (%)
History of any revascularization (%)
Revascularization for angina or MI (%)
Number of diseased vessels, median (25th, 75th percentile)
Pretreatment with PTCA (%) 1
Stent count, median (25th, 75th percentile)
Post-procedural LOS, median (25th, 75th percentile)
Cypher (Cordis Corporation), Endeavor (Medtronic).
LOS length of hospital stay; MImyocardial infarction; PTCA percutaneous transluminal co
Table 2. 3-Year Clinical Outcomes
Outcomes
Even
Cypher
(n  113)
Death (%) 7.2
Nonfatal MI (%) 4.5
Stroke (%) 1.8
TVRs (events/100 subjects)
PCI 12.2
CABG 0.0
Total 12.2
Non-TVRs (events/100 subjects)
PCI 21.4
CABG 0.0
Total 21.4
Total revascularizations (events/100 subjects)
PCI 31.8
CABG 0.0
Total 31.8
Composite time-to-event outcomes (%)
Death or MI 10.8
Death or MI or TVR 18.7
Cypher (Cordis Corporation), Endeavor (Medtronic).CABG coronary artery bypass graft surgery; CI confidence interval; MImyocardial infarction; PCIomprehensive cost-effectiveness ratio averaged $57,002/
ALY saved after discounting. However, these point esti-
ates were highly variable (Fig. 4). At the end of 3 years of
ollow-up, the comprehensive cost-effectiveness ratio for a
ES versus a SES treatment strategy cost $50,000/
ALY in 41.0% of bootstrap samples.
pher
113)
Endeavor
(n  323) p Value
1 (53, 72) 61 (54, 69) 0.67
3 (18.3) 112/323 (34.7) 0.001
3 (9.7) 25/323 (7.7) 0.55
3 (75.2) 212/319 (66.5) 0.10
3 (28.3) 96/319 (29.7) 0.81
3 (86.7) 268/319 (83.5) 0.46
3 (74.3) 227/319 (70.7) 0.54
3 (20.7) 64/321 (19.9) 0.89
3 (23.9) 85/321 (26.3) 0.71
3 (86.7) 274/323 (84.8) 0.76
0 (1.0, 2.0) 1.0 (1.0, 2.0) 0.40
3 (96.5) 320/323 (99.1) 0.057
0 (1.0, 1.0) 1.0 (1.0, 1.0) 0.44
0 (1.0, 2.0) 1.0 (1.0, 1.0) 0.21
angioplasty.
s
Difference
(95% CI) p Value
Endeavor
(n  323)
3.3 4.0 (1.3 to 9.1) 0.14
0.6 3.8 (0.1 to 7.7) 0.005
0.6 1.2 (1.4 to 3.8) 0.38
16.0 3.8 (13.0 to 5.4) 0.42
1.9 1.9 (3.4 to0.4) 0.013
17.9 5.7 (15.1 to 3.7) 0.23
22.8 1.4 (13.1 to 10.4) 0.82
2.6 2.6 (4.3 to0.8) 0.004
25.4 4.0 (16.1 to 8.1) 0.52
36.0 4.2 (19.2 to 10.8) 0.58
3.5 3.5 (5.7 to1.3) 0.002
39.5 7.7 (23.1 to 7.7) 0.32
3.9 6.9 (0.8 to 13.0) 0.028
18.6 0.2 (8.3 to 8.6) 0.97Cy
(n 
6
21/11
11/11
85/11
32/11
98/11
84/11
23/11
27/11
98/11
1.
09/11
1.
1.t Ratepercutaneous coronary intervention; TVR target vessel revascularization.
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1203iscussion
n the ENDEAVOR III clinical trial, a treatment strategy
nvolving the use of the ZES versus the SES was associated
ith a significant reduction in death or MI at 3-year
ollow-up. Although overall TVR did not differ, an excess of
ABG-related TVR occurred in subjects receiving ZES.
here were no significant differences in other clinical or
conomic outcomes. These disparate findings were unex-
ected in a trial of 2 DES and raise several important
uestions. First, are the clinical results for subjects receiving
ES and SES in the present study consistent with results
rom other DES versus DES clinical trials involving ZES
nd SES? Second, is there reason to believe that the MI
enefit of ZES versus SES will translate into a future
urvival benefit? Third, are the economic results from this
tudy consistent with those from previous DES versus BMS
conomic analyses involving ZES and SES?
omparison with other DES versus DES trials. Several trials
ave compared the relative safety and efficacy outcomes after
reatment with SES and paclitaxel-eluting stents (PES). In
meta-analysis of 38 randomized trials comparing SES,
ES, and BMS (n  18,023) with follow-up extending to
years, similar rates of survival for all 3 stent groups were
bserved (21). Overall, there were no significant differences
n the risk of definite stent thrombosis through 4-year
ollow-up for either DES relative to BMS, although the risk
f definite late stent thrombosis (30 days to 4 years) was
ignificantly higher with PES compared with the BMS and
ES patient groups. Similar differences in the occurrence of
tent thrombosis between SES and PES have been reported
n a recent meta-analysis of randomized trials (8) in addition
o observational registries (22,23). Such differences have not
een consistently observed in individual randomized trials
omparing SES and PES that might be underpowered to
etect these differences (5,24,25).
A pooled analysis of 4 randomized trials of SES versus
MS (n  1,748) and 5 randomized trials of PES versus
MS (n  3,513) reported no differences in all-cause
ortality, MI, and death or MI between the 2 DES versus
MS. However, the use of both DES was associated with
ignificant reductions in both target lesion revascularization
TLR) and TVR procedures (26). Of note, although this
tudy’s 4-year all-cause mortality rate for SES was less than
he 3-year mortality rate in the ENDEAVOR III trial, the
I rate was greater.
Other randomized trials have observed differences in
afety outcomes among the various types of DES. The
NDEAVOR IV (Randomized, Controlled Trial of the
edtronic Endeavor Drug [ABT-578] Eluting Coronary
tent System Versus the Taxus Paclitaxel-Eluting Coronary
tent System in De Novo Native Coronary Artery Lesions)
rial enrolled 1,548 patients with clinical and angiographic0.00
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Figure 1. Cumulative Events
(A) Target vessel revascularization (TVR): 3-year cumulative TVR rates
according to randomization to the Cypher (Cordis Corporation) versus
Endeavor (Medtronic) drug-eluting stent (DES). (B) Non-TVR: 3-year cumula-
tive non-TVR rates according to randomization to the Cypher versus
Endeavor DES. (C) Time to death or MI: 3-year cumulative death or myocar-
dial infarction event rates according to randomization to the Cypher versusharacteristics similar to the ENDEAVOR III trial and
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1204andomized them to either ZES or PES (27). The rate of
I was significantly lower in the ZES group compared with
he PES cohort at 2-year follow-up (2.0% vs. 4.1%, p 
.02) (27). The SORT-OUT III (Danish Organization on
andomized Trials With Clinical Outcome) randomized
rial of ZES versus SES identified significant differences in
tent thrombosis, MI, and TLR favoring SES (6). However,
he safety and efficacy outcomes observed with SES in the
ORT-OUT III trial differ from SES outcomes in other
rials of similar design and study population (5,28). More
ecently, the ZEST (Zotarolimus-Eluting Stent Versus
irolimus-Eluting Stent and PacliTaxel-Eluting Stent for
oronary Lesions) trial that compared ZES, SES, and PES
ound no differences in death or in MI at 1-year follow-up,
hereas the SPIRIT III (Clinical Evaluation of the Xience
Everolimus Eluting Coronary Stent System in the Treat-
ent of Patients with de novo Native Coronary Artery
esions) trial reported a borderline significant reduction in
eath or MI (p  0.055) for everolimus-eluting stent versus
ES at 2 years (7,29).
onfatal MIs. In the ENDEAVOR III trial, the percentage
f SES subjects experiencing an index hospital stay MI was
imilar to that observed in the SIRIUS (Sirolimus-Eluting
Table 3. 3-Year Hospital Stays
Event Rat
Cypher
(n  113)
Hospital stay types (per 100 subjects)
Revascularization 31.8
Other cardiac 23.0
Noncardiac 62.3
Total (per 100 subjects) 117.1
Total length of stay (days) 5.44
Cypher (Cordis Corporation), Endeavor (Medtronic).
CI confidence interval.
Table 4. 3-Year Quality-Adjusted Survival and Medical Costs
Cypher
(n  113)
Survival (days) 1,053
Discount* survival (days) 1,007
Quality-adjusted survival (days) 862
Discount* QA survival (days) 824
Medical costs ($)
Initial year 17,912
Second year 1,994
Third year 2,072
Cumulative 3-yr costs 21,978
Cumulative discount* 3-yr costs 21,657
Cypher (Cordis Corporation), Endeavor (Medtronic). *Discount rate of 3%/year.CI confidence interval.alloon Expandable Stent in the Treatment of Patients
ith De Novo Native Coronary Artery Lesions) trial (30),
hereas the percentage for ZES subjects was less than that
eported in the ENDEAVOR II trial. Results from the
NDEAVOR IV trial serve to confirm the ENDEAVOR
II MI findings (31). During the ENDEAVOR IV trial,
ndex hospital stay MIs occurred in 0.8% of subjects
eceiving ZES versus 2.1% of subjects receiving PES (p 
.051), demonstrating a lower initial MI rate for ZES
ubjects. The ENDEAVOR IV side branch occlusion study
eported associations among use of the ZES stent, the
ccurrence of fewer side branch occlusions, and lower MI
ates (32). Although this also might explain the differences
n MI rates for ZES versus SES in the ENDEAVOR III
rial, further investigation is needed.
Although the ENDEAVOR III trial provided evidence of a
eduction in death or MI with the use of the ZES versus SES,
hese results did not translate into significant differences in
uality-adjusted survival at 3-year follow-up. However, previ-
us researchers have concluded that there is an association
etween creatine kinase-myocardial band (CK-MB) elevation
fter PCI procedures and higher risks of death, subsequent
ardiac events, and greater medical costs (33). This risk level
Difference
(95% CI) p Value
Endeavor
(n  323)
39.2 7.4 (22.8 to 7.9) 0.34
36.0 13.0 (28.5 to 2.5) 0.099
65.0 2.6 (64.7 to 18.6) 0.28
140.1 23.0 (64.7 to 18.6) 0.28
6.16 0.72 (1.92 to 0.47) 0.24
deavor
 323)
Difference
(95% CI) p Value
1,065 12 (36 to 11) 0.31
1,018 11 (33 to 11) 0.31
874 12 (32 to 9) 0.26
834 11 (30 to 8) 0.27
9,163 1,251 (2,915 to 413) 0.14
2,565 572 (1,864 to 710) 0.38
1,999 74 (959 to 1,107) 0.89
3,727 1,749 (4,638 to 1,140) 0.24
3,353 1,696 (4,482 to 1,089) 0.23esEn
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1205eems to increase as a continuous function (with no “cutoff”
alue) and is particularly elevated in patients with side branch
cclusions. It has been shown that patients with low CK-MB
levations—such as most subjects with nonfatal MIs in the
NDEAVOR III trial—have elevated intermediate and long-
erm risks that extend well beyond 3-year follow-up and
nclude patients whose peak CK-MB levels did not exceed 2
imes the upper limit of normal (34–36). It remains to be seen
hether the 5-year ENDEAVOR III results will provide
urther evidence regarding relationships between treatment-
elated differences in nonfatal MIs and other clinical outcomes
n this study.
conomic comparisons with DES versus BMS trials. Previous
conomic analyses have evaluated the Cypher (Cordis Cor-
oration) DES in the SIRIUS trial and the Endeavor
Medtronic) DES in the ENDEAVOR II trial (3,4). The
VR results from these studies are consistent with those
rom the ENDEAVOR III trial—most TVR procedures
ccurred during the first follow-up year (31) (The SIRIUS
tudy: 5-Year Outcomes, unpublished work, 2008).
Although the timing of TVR events in the ENDEAVOR
II trial is consistent with the results from the SIRIUS and
NDEAVOR II trials, the frequency of these events differs.
he percentage of ENDEAVOR III SES subjects undergoing
LR in the first year is somewhat less than in the SIRIUS trial,
hereas the TLR percentage for ZES subjects in the
NDEAVOR III trial is somewhat greater than in the
NDEAVOR II trial. Although these TLR differences are
ikely not significant, they—and the fact that all CABG
rocedures occurred in subjects receiving ZES stents—are
ssociated with greater 3-year medical costs for ZES subjects in
he ENDEAVOR III trial ($23,727) than was previously
eported for the ENDEAVOR II trial ($20,536) (4).
tudy limitations. Economic and quality-of-life data were not
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Figure 2. Cumulative Quality-Adjusted Survival
3-year cumulative quality-adjusted survival according to randomization to
the Cypher (Cordis Corporation) drug-eluting stent versus the Endeavor
(Medtronic) drug-eluting stent.rospectively collected alongside the ENDEAVOR III clinicalrial. This limitation prevented certain cost elements (outpa-
ient and medication costs) from being included in our work.
owever, this is not a critical factor in the present study,
ecause all subjects were prescribed dual antiplatelet therapy for
minimum of 3 months and aspirin indefinitely, and the only
ignificant treatment-related differences between subjects re-
eiving ZES and SES were in index hospital stay nonfatal MIs
nd follow-up period CABG procedures. We believe that our
ethodology ensured that the results accurately reflect the
edical cost and quality-adjusted survival implications of all
linical end point differences observed during the EN-
EAVOR III trial. A second limitation of the present analysis
s that the observed follow-up period ended at 3 years.
lthough it would have been informative to include longer-
erm clinical estimates, we do not believe that the trends
bserved during the first 3 years will be reversed during
ubsequent follow-up years. Lastly, the ENDEAVOR III trial
as underpowered to adequately evaluate differences in clinical
nd economic results. Whether the results observed in this
tudy can be generalized to the real-world population of
atients undergoing PCI procedures with ZES and SES will
eed to be determined. The outcomes from this study also
iffer from the disparate results from the SORT-OUT III and
EST trials. Future researchers will need to determine the
xtent to which the ENDEAVOR III results are anomalous or
epresentative of results one would expect in other populations.
onclusions
se of Endeavor (Medtronic) versus Cypher (Cordis Cor-
oration) led to reductions in death or MI, with no
ifference in total revascularizations and medical costs.
hese findings are unexpected in DES comparisons. If
uture trials observe similar differences, the use of Endeavor
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Figure 3. Cumulative Medical Costs
3-year cumulative medical costs according to randomization to the Cypher
(Cordis Corporation) drug-eluting stent versus the Endeavor (Medtronic)
drug-eluting stent.
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1206Medtronic) versus Cypher (Cordis Corporation) will be
conomically attractive by conventional standards.
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